GlaxoSmithKline has agreed to acquire Canadian biopharmaceutical company 35Pharma Inc. for $950 million, adding HS235, an investigational pulmonary hypertension treatment, to its clinical pipeline. The compound targets the activin receptor signalling pathway, a mechanism representing a new therapeutic approach within the pulmonary hypertension treatment landscape.
The transaction represents GSK's latest investment in the pulmonary hypertension space, following its $2.2 billion acquisition of RAPT Therapeutics and a concurrent licensing agreement with Frontier Biotechnologies. These strategic moves position the pharmaceutical giant to capture market share in a therapeutic area projected to reach $18 billion globally by 2032, driven by increasing disease awareness and limited treatment options.
The pulmonary hypertension market has become an attractive area for consolidation as multiple drug classes demonstrate clinical benefit. GSK's multi-pronged acquisition strategy suggests the company is building a comprehensive portfolio to address various patient populations and disease stages within the indication.